EUVIMEDEUVIMED entdecken
Crossref

Chimeric Antigen Receptor Regulatory T Cells Targeted Against Oxidized Low-Density Lipoprotein Reduce Atherosclerotic Plaque Development

Robert D Schwab iD, David Degaramo, Seok Jae Hong iD, Xin Bi, Aisha Faruqi, William Aguilar, Shawna K Brookens iD, John T Keane, Fang Liu iD, Kiran Musunuru iD, Daniel J Rader iD, Avery D Posey iD

Circulation · 03.02.2026 · 153 (5) · 319-337

DOI: 10.1161/circulationaha.125.073987 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 03.02.2026. Verfasst von Robert D Schwab und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine (R.D.S., X.B., A.F., K.M., D.J.R.), Perelman School of Medicine, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Lipoproteins, LDL, T-Lymphocytes, Regulatory, Plaque, Atherosclerotic, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: U.S. Department of Veterans Affairs, HHS | NIH | National Heart, Lung, and Blood Institute, American Society of Hematology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cardiovascular disease caused by atherosclerosis is responsible for 18 million deaths annually, highlighting a need for new medical therapies, especially for patients who are not eligible for percutaneous intervention. Atherosclerosis is driven by the accumulation of low-density lipoprotein and the formation of foam cells, accompanied by oxidative stress and the accumulation of oxidized low-density lipoprotein (OxLDL), a proinflammatory molecule. Lowering low-density lipoprotein levels is the mainstay of current treatment, along with blood pressure control and lifestyle changes, but to date, it has not been feasible to specifically target inflammatory pathways contributing to plaque development without considerable systemic side effects. Over the past decade, chimeric antigen receptor T cells have been used to treat cancer, resolve cardiac fibrosis, and restore immune balance in autoimmune diseases. In some instances, regulatory T cells endowed with chimeric antigen receptor (CAR Tregs) have been developed to treat autoimmunity through antigen-specific immunosuppression. METHODS: Using an inducible regulatory T cell platform, we created an anti-OxLDL–specific CAR Treg therapy and evaluated cell- and cytokine-mediated immunosuppression to reduce macrophage foam cell formation in vitro. We then tested murine anti-OxLDL CAR Tregs in immunocompetent mouse models of hyperlipidemia and atherosclerosis. RESULTS: Anti-OxLDL CAR Tregs reduced macrophage foam cell formation in vitro and significantly inhibited atherosclerotic plaque formation in vivo in immunocompetent mouse models. CONCLUSIONS: Anti-OxLDL CAR Tregs mitigate inflammation and plaque deposition associated with OxLDL and may offer a new therapeutic option for atherosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoproteins, LDLT-Lymphocytes, RegulatoryPlaque, AtheroscleroticReceptors, Chimeric AntigenAtherosclerosisImmunotherapy, AdoptiveAnimalsMiceFoam CellsHumansMice, Inbred C57BLDisease Models, AnimalMale

Stichwörter der Autor:innen

atherosclerosiscardiovascular diseasesinflammationreceptors, chimeric antigen

Substanzen

Lipoproteins, LDLoxidized low density lipoproteinReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Departments of Medicine (R.D.S., X.B., A.F., K.M., D.J.R.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Systems Pharmacology and Translational Therapeutics (D.D., W.A., S.K.B., J.T.K., F.L., A.D.P.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Pathology and Laboratory Medicine (S.J.H.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA (A.D.P.).

ORCID-Profile: Robert D Schwab, Seok Jae Hong, Shawna K Brookens, Fang Liu, Kiran Musunuru, Daniel J Rader, Avery D Posey

Förderung

  • U.S. Department of Veterans Affairs
  • HHS | NIH | National Heart, Lung, and Blood Institute
  • American Society of Hematology

Zitieren

APA

Schwab, R. D., Degaramo, D., Hong, S. J., Bi, X., Faruqi, A., Aguilar, W., Brookens, S. K., Keane, J. T., Liu, F., Musunuru, K., Rader, D. J., & Posey, A. D. (2026). Chimeric Antigen Receptor Regulatory T Cells Targeted Against Oxidized Low-Density Lipoprotein Reduce Atherosclerotic Plaque Development. Circulation, 153(5), 319-337. https://doi.org/10.1161/circulationaha.125.073987

Vancouver

Schwab RD, Degaramo D, Hong SJ, Bi X, Faruqi A, Aguilar W, et al. Chimeric Antigen Receptor Regulatory T Cells Targeted Against Oxidized Low-Density Lipoprotein Reduce Atherosclerotic Plaque Development. Circulation. 2026;153(5):319-337. doi:10.1161/circulationaha.125.073987

BibTeX
@article{Schwab2026,
  author = {Schwab, Robert D and Degaramo, David and Hong, Seok Jae and Bi, Xin and Faruqi, Aisha and Aguilar, William and Brookens, Shawna K and Keane, John T and Liu, Fang and Musunuru, Kiran and Rader, Daniel J and Posey, Avery D},
  title = {Chimeric Antigen Receptor Regulatory T Cells Targeted Against Oxidized Low-Density Lipoprotein Reduce Atherosclerotic Plaque Development},
  journal = {Circulation},
  year = {2026},
  volume = {153},
  number = {5},
  pages = {319--337},
  doi = {10.1161/circulationaha.125.073987}
}
Kostenlos starten →